Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

TRAIL Mediated Signaling in Pancreatic Cancer

  • Nogueira, Daniele Rubert (Department of Industrial Pharmacy, Health Science Center, Federal University of Santa Maria) ;
  • Yaylim, Ilhan (Department of Molecular Medicine, Institute of Experimental Medicine, Istanbul University) ;
  • Aamir, Qurratulain (Department of Anatomy, Rashid Latif Medical College) ;
  • Kahraman, OzlemTimirci (Department of Molecular Medicine, Institute of Experimental Medicine, Istanbul University) ;
  • Fayyaz, Sundas (Laboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College) ;
  • Naqvi, Syed Kamran-Ul-Hassan (COMSATS Institute of Information Technology) ;
  • Farooqi, Ammad Ahmad (Laboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Research over the years has progressively shown substantial broadening of the tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL)-mediated signaling landscape. Increasingly it is being realized that pancreatic cancer is a multifaceted and genomically complex disease. Suppression of tumor suppressors, overexpression of oncogenes, epigenetic silencing, and loss of apoptosis are some of the extensively studied underlying mechanisms. Rapidly accumulating in vitro and in vivo evidence has started to shed light on the resistance mechanisms in pancreatic cancer cells. More interestingly a recent research has opened new horizons of miRNA regulation by DR5 in pancreatic cancer cells. It has been shown that DR5 interacts with the core microprocessor components Drosha and DGCR8, thus impairing processing of primary let-7. Xenografting DR5 silenced pancreatic cancer cells in SCID-mice indicated that there was notable suppression of tumor growth. There is a paradigm shift in our current understanding of TRAIL mediated signaling in pancreatic cancer cells that is now adding new layers of concepts into the existing scientific evidence. In this review we have attempted to provide an overview of recent advances in TRAIL mediated signaling in pancreatic cancer as evidenced by findings of in vitro and in vivo analyses. Furthermore, we discuss nanotechnological advances with emphasis on PEG-TRAIL and four-arm PEG cross-linked hyaluronic acid (HA) hydrogels to improve availability of TRAIL at target sites.

Keywords

References

  1. Arlt A, Muerkoster SS, Schafer H (2013). Targeting apoptosis pathways in pancreatic cancer. Cancer Lett, 332, 346-58. https://doi.org/10.1016/j.canlet.2010.10.015
  2. Bae S, Ma K, Kim TH, et al (2012). Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials, 33, 1536-46. https://doi.org/10.1016/j.biomaterials.2011.10.050
  3. Bai J, Sui J, Demirjian A, et al (2005). Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res, 65, 2344-52. https://doi.org/10.1158/0008-5472.CAN-04-3502
  4. Basu A, Haldar S (2009). Anti-proliferative and proapoptotic effects of benzyl isothiocyanate on human pancreatic cancer cells is linked to death receptor activation and RasGAP/Rac1 down-modulation. Int J Oncol, 35, 593-9.
  5. Braeuer SJ, Buneker C, Mohr A, Zwacka RM (2006). Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by upregulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res, 4, 715-28. https://doi.org/10.1158/1541-7786.MCR-05-0231
  6. Byeon HJ, Choi SH, Choi JS, et al (2013). Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosisinducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model. Biomed Pharmacother, 68, 65-9.
  7. Byeon HJ, Choi SH, Choi JS, et al (2014). Four-arm PEG crosslinked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer. ActaBiomater, 10, 142-50.
  8. Chen S, Wang G, Niu X, et al (2014). Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Lett. Feb, 348, 20-8. https://doi.org/10.1016/j.canlet.2014.02.010
  9. Chen Z, Sangwan V, Banerjee S, et al (2014). Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway. Cancer Lett, 348, 156-66. https://doi.org/10.1016/j.canlet.2014.03.016
  10. Diamantidis M, Tsapournas G, Kountouras J, Zavos C (2008). New aspects of regulatory signaling pathways and novel therapies in pancreatic cancer. Curr Mol Med, 8, 12-37. https://doi.org/10.2174/156652408783565586
  11. Ding J, Polier G, Kohler R, et al (2012). Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and upregulation of TRAIL receptor 2 expression. J Biol Chem, 287, 641-9. https://doi.org/10.1074/jbc.M111.286526
  12. Ding N, Cui XX, Gao Z, et al (2014). A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors. Int J Oncol, 44, 2139-45.
  13. Forero-Torres A, Infante JR, Waterhouse D, et al (2013). Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer. Cancer Med, 2, 925-32. https://doi.org/10.1002/cam4.137
  14. Fu J, Rodova M, Roy SK, et al (2013). GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett, 330, 22-32. https://doi.org/10.1016/j.canlet.2012.11.018
  15. Garg G, Gibbs J, Belt B, et al (2014). Novel treatment option for MUC16-positive malignancies with the targeted TRAILbased fusion protein Meso-TR3. BMC Cancer, 14, 35. https://doi.org/10.1186/1471-2407-14-35
  16. Groth A, Salnikov AV, Ottinger S, et al (2012). New geneimmunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 Bispecific antibody for tumor targeting. Clin Cancer Res, 18, 1028-38. https://doi.org/10.1158/1078-0432.CCR-11-2767
  17. Guo L, Fan L, Ren J, et al (2011). A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes. Nanotechnology, 22, 265105. https://doi.org/10.1088/0957-4484/22/26/265105
  18. Guo L, Fan L, Ren J, et al (2012). Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer. Int J Nanomedicine, 7, 1449-60.
  19. Haag C, Stadel D, Zhou S, et al (2011). Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. Gut, 60, 225-37. https://doi.org/10.1136/gut.2009.202325
  20. Hafeez BB, Mustafa A, Fischer JW, et al (2014). $\alpha$-Mangostin: a Dietary antioxidant derived from the pericarp of Garcinia mangostana L. inhibits pancreatic tumor growth in xenograft mouse model. Antioxid Redox Signal, doi:10.1089/ars.2013.5212..
  21. Haselmann V, Kurz A, Bertsch U, et al (2014). Nuclear death receptor TRAIL-R2 inhibits maturation of Let-7 and promotes proliferation of pancreatic and other tumor cells. Gastroenterology, 146, 278-90. https://doi.org/10.1053/j.gastro.2013.10.009
  22. Hinz S, Trauzold A, Boenicke L, et al (2000). Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAILreceptor-mediated apoptosis. Oncogene, 19, 5477-86. https://doi.org/10.1038/sj.onc.1203936
  23. Hoshi H, Sawada T, Uchida M, et al (2013). MUC5AC protects pancreatic cancer cells from TRAIL-induced death pathways. Int J Oncol, 42, 887-93.
  24. Huang M, Tang SN, Upadhyay G, et al (2014). Embelin suppresses growth of human pancreatic cancer xenografts, and pancreatic cancer cells isolated from KrasG12D mice by inhibiting akt and sonic hedgehog pathways. PLoS One, 2, 92161.
  25. Ibrahim SM, Ringel J, Schmidt C, et al (2001). Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas, 23, 72-9. https://doi.org/10.1097/00006676-200107000-00011
  26. Kannappan R, Ravindran J, Prasad S, et al (2010). Gammatocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors. Mol Cancer Ther, 9, 2196-207. https://doi.org/10.1158/1535-7163.MCT-10-0277
  27. Kim H, Zhai G, Samuel SL, et al (2012). Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma. Mol Cancer Ther, 11, 405-15. https://doi.org/10.1158/1535-7163.MCT-11-0581
  28. Kim JH, Park B, Gupta SC, et al (2012). Zyflamend sensitizes tumor cells to TRAIL-induced apoptosis through upregulation of death receptors and down-regulation of survival proteins: role of ROS-dependent CCAAT/enhancer-binding protein-homologous protein pathway. Antioxid Redox Signal, 16, 413-27. https://doi.org/10.1089/ars.2011.3982
  29. Kong R, Jia G, Cheng ZX, et al (2012). Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5. PLoS One, 7, 37222. https://doi.org/10.1371/journal.pone.0037222
  30. LaCasse EC, Cherton-Horvat GG, Hewitt KE, et al (2006). Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res, 12, 5231-41. https://doi.org/10.1158/1078-0432.CCR-06-0608
  31. Lan X, Sun H, Liu J, et al (2013). Effects of garlic oil on pancreatic cancer cells. Asian Pac J Cancer Prev, 14, 5905-10. https://doi.org/10.7314/APJCP.2013.14.10.5905
  32. Lee AL, Dhillon SH, Wang Y, et al (2011). Synergistic anticancer effects via co-delivery of TNF-related apoptosisinducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles. MolBiosyst, 7, 1512-22.
  33. Lee AL, Wang Y, Pervaiz S, Fan W, Yang YY (2011). Synergistic anticancer effects achieved by co-delivery of TRAIL and paclitaxel using cationic polymeric micelles. MacromolBiosci, 11, 296-307.
  34. Liao Q, Friess H, Kleeff J, Buchler MW (2001). Differential expression of TRAIL-R3 and TRAIL-R4 in human pancreatic cancer. Anticancer Res, 21, 3153-9.
  35. Lim SM, Kim TH, Jiang HH, et al (2011). Improved biological half-life and anti-tumor activity of TNF-related apoptosisinducing ligand (TRAIL) using PEG-exposed nanoparticles. Biomaterials, 32, 3538-46. https://doi.org/10.1016/j.biomaterials.2011.01.054
  36. Liu Q, Chen W, Jiao Y, et al (2014). Pulsatilla saponin A, an active molecule from Pulsatilla chinensis, induces cancer cell death and inhibits tumor growth in mouse xenograft models. J Surg Res, 188, 387-95. https://doi.org/10.1016/j.jss.2014.01.026
  37. Liu Y, Cui YF (2013). Synergism of cytotoxicity effects of triptolide and artesunate combination treatment in pancreatic cancer cell lines. Asian Pac J Cancer Prev, 14, 5243-8. https://doi.org/10.7314/APJCP.2013.14.9.5243
  38. Mangipudi SS, Canine BF, Wang Y, Hatefi A (2009). Development of a genetically engineered biomimetic vector for targeted gene transfer to breast cancer cells. Mol Pharm, 6, 1100-9. https://doi.org/10.1021/mp800251x
  39. Matsuzaki H, Schmied BM, Ulrich A, et al (2001). Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res, 7, 407-14.
  40. Miao L, Zhang K, Qiao C, et al (2013). Antitumor effect of human TRAIL on adenoid cystic carcinoma using magnetic nanoparticle-mediated gene expression. Nanomedicine, 9, 141-50. https://doi.org/10.1016/j.nano.2012.04.006
  41. Ozawa F, Friess H, Kleeff J, et al (2001). Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett, 163, 71-81. https://doi.org/10.1016/S0304-3835(00)00660-1
  42. Petrangolini G, Tortoreto M, Perego P, et al (2008). Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. Cancer BiolTher, 7, 596-601.
  43. Roder C, Trauzold A, Kalthoff H (2011). Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma. Eur J Cell Biol, 90, 450-5. https://doi.org/10.1016/j.ejcb.2010.10.008
  44. Sharma R, Buitrago S, Pitoniak R, et al (2014). Influence of the implantation site on the sensitivity of patient pancreatic tumor xenografts to Apo2L/TRAIL therapy. Pancreas, 43, 298-305. https://doi.org/10.1097/MPA.0000000000000099
  45. Stadel D, Mohr A, Ref C, et al (2010). TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res, 16, 5734-49. https://doi.org/10.1158/1078-0432.CCR-10-0985
  46. Stan SD, Singh SV, Whitcomb DC, Brand RE (2013). Phenethyl isothiocyanate inhibits proliferation and induces apoptosis in pancreatic cancer cells in vitro and in a MIAPaca2 xenograft animal model. Nutr Cancer, 66, 747-55.
  47. Thomas RP, Farrow BJ, Kim S, et al (2002). Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery, 132, 127-34. https://doi.org/10.1067/msy.2002.124930
  48. Trauzold A, Wermann H, Arlt A, et al (2001). CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene, 20, 4258-69. https://doi.org/10.1038/sj.onc.1204559
  49. Vogler M, Walczak H, Stadel D, et al (2008). Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res, 68, 7956-65. https://doi.org/10.1158/0008-5472.CAN-08-1296
  50. Wang Y, Zhou Y, Jia G, et al (2014). Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: involvement of NF-kB signaling pathway. Biochem Pharmacol, 88, 322-33. https://doi.org/10.1016/j.bcp.2014.01.041
  51. Zhang JS, Herreros-Vilanueva M, Koenig A, et al (2014). Differential activity of GSK-3 isoforms regulates NF-kB andTRAIL- or $TNF\alpha$ induced apoptosis in pancreatic cancer cells. Cell Death Dis, 5, 1142. https://doi.org/10.1038/cddis.2014.102
  52. Zhao B, Li L, Cui K, et al (2011). Mechanisms of TRAIL and gemcitabine induction of pancreatic cancer cell apoptosis. Asian Pac J Cancer Prev, 12, 2675-8.
  53. Zhou DH, Yang LN, Roder C, Kalthoff H, Trauzold A (2013). TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xl in pancreatic ductal adenocarcinoma cells. Hepatobiliary Pancreat Dis Int, 12, 94-8. https://doi.org/10.1016/S1499-3872(13)60012-0

Cited by

  1. TRAIL Suppresses Human Breast Cancer Cell Migration via MADD/CXCR7 vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2751
  2. Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance? vol.12, pp.6, 2017, https://doi.org/10.1371/journal.pone.0178703
  3. Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer vol.9, pp.1, 2019, https://doi.org/10.1038/s41598-018-37433-6